ALDEYRA THERAPEUTICS, INC.

Class 005: Pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

Class 005: Pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

Class 005: Pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

pharmaceuticals in the nature of an injectable solution for intravitreal use  for the prevention of eye conditions including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and retinitis pigmentosa

pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

pharmaceuticals in the nature of eye drops for the treatment of dry eye disease and allergic conjunctivitis

Pharmaceutical agents for Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase Inhibition, and by Heat Shock Protein 90 and chaperome Inhibition for the treatment of immune-mediated diseases, dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, Sjögren-Larsson Syndrome, immune-mediated ocular diseases, systemic diseases, proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer; pharmaceuticals for use in treatment of immune-mediated diseases; pharmaceuticals for use in treating dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome; pharmaceuticals for treating immune-mediated ocular diseases and systemic diseases; pharmaceuticals for treating proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer

Class 005: Pharmaceutical agents for lowering aldehyde levels by trapping aldehydes

Pharmaceutical preparations for treating disease, namely, inflammation, fibrosis, and excessive tissue dryness; pharmaceutical agents for trapping aldehydes for use in the treatment of inflammation, fibrosis, and excessive tissue dryness